Compare · BWAY vs RMD
BWAY vs RMD
Side-by-side comparison of BrainsWay Ltd. (BWAY) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BWAY and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $27.05B, about 48.1x BWAY ($562.1M).
- Over the past year, BWAY is up 175.0% and RMD is down 24.5% - BWAY leads by 199.5 points.
- BWAY has been more active in the news (10 items in the past 4 weeks vs 7 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 5 for BWAY).
- Company
- BrainsWay Ltd.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $562.1M
- $27.05B
- 1M return
- -14.41%
- -10.85%
- 1Y return
- +174.95%
- -24.50%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 10
- 7
- Recent ratings
- 5
- 25
BrainsWay Ltd.
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest BWAY
- Chief Scientist Roth Yiftach sold 7,000 units of Ordinary Shares, decreasing direct ownership by 0.65% to 1,072,305 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.
- Director Mitrany Rayten Michal Ety sold 17,980 units of Ordinary Shares, decreasing direct ownership by 59% to 12,500 units (SEC Form 4)
- Director Mitrany Rayten Michal Ety converted options into 27,500 units of Ordinary Shares and covered exercise/tax liability with 9,520 units of Ordinary Shares, increasing direct ownership by 144% to 30,480 units (SEC Form 4)
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Announces Minority-Stake Investment in Hopemark Health
- SEC Form 6-K filed by BrainsWay Ltd.
- Amendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.